Bristol-Myers Squibb Company (BMY): Business Model Canvas [June-2026 Updated]

This ready-made Business Model Canvas gives you a clear, research-based view of Bristol-Myers Squibb Company, showing how it builds value through oncology and immunology R&D, clinical trials, licensing, global commercialization, and AI tools, supported by partners such as Microsoft, Anthropic, Hengrui Pharma, and Orbital Therapeutics. You'll see the main growth drivers, including $10B annual R&D spend, a late-stage pipeline, a global commercial and manufacturing base, and seven $1B+ products, along with the key customer segments, hospitals, specialty pharmacies, revenue streams, and cost pressures that shape its specialty medicine strategy.

Bristol-Myers Squibb Company - Canvas Business Model: Key Partnerships

4 named partners appear in this chapter: 2 AI/data partners and 2 therapeutic partners.

2 partnerships sit on the technology side and 2 sit on the drug-development side.

Microsoft

• 1 collaboration
• 0 publicly disclosed dollar terms in this chapter
• AI and cloud infrastructure

Anthropic

• 1 collaboration
• 0 publicly disclosed dollar terms in this chapter
• Generative AI

Hengrui Pharma

• 1 partnership
• 0 publicly disclosed dollar terms in this chapter
• Drug licensing and development

Orbital Therapeutics

• 1 partnership
• 0 publicly disclosed dollar terms in this chapter
• Cell therapy development

Bristol-Myers Squibb Company - Canvas Business Model: Key Activities

Bristol-Myers Squibb Company's key activities are built around oncology and immunology research, clinical development, deal-making, and global medicine sales. The biggest public dollar signals are the $74.0B Celgene acquisition, the $13.1B MyoKardia acquisition, the $4.1B Turning Point Therapeutics acquisition, the $4.8B Mirati Therapeutics acquisition, the $14.0B Karuna Therapeutics acquisition, and the $4.1B RayzeBio acquisition.

Oncology and immunology R&D. This is the core science engine. Company Name uses internal discovery and outside assets to build its pipeline in cancer, immune disease, and related specialty areas. The scale of this activity shows up in transaction values because Company Name has repeatedly bought late-stage and platform science instead of relying only on internal labs. The largest disclosed examples are the $74.0B Celgene transaction, the $13.1B MyoKardia transaction, and the $4.1B Turning Point Therapeutics transaction. Each number matters because it shows how much capital Company Name is willing to put into future drug candidates before they become commercial products.

• $74.0B Celgene added scale in oncology and hematology.
• $13.1B MyoKardia added cardiovascular science and platform assets.
• $4.1B Turning Point Therapeutics added precision oncology assets.

Clinical trials and regulatory filings. Company Name turns molecules into medicines through Phase 1, Phase 2, and Phase 3 studies, then submits NDA, BLA, sNDA, and sBLA filings. Phase 1 tests safety and dose, Phase 2 looks for early efficacy, and Phase 3 is the confirmatory stage that supports approval decisions. This matters because every approved label extension can add revenue without building a brand-new drug from scratch. The regulatory activity is not optional; it is the gate between research spend and sales.

• Phase 1
• Phase 2
• Phase 3
• NDA
• BLA
• sNDA
• sBLA

Business development and licensing. Company Name uses acquisitions and licensing-style structures to buy time, pipeline depth, and technical capability. The table above shows the financial shape of that strategy: $14.0B for Karuna, $4.1B for RayzeBio, and $4.8B for Mirati show a steady willingness to pay for late-stage and differentiated assets. This matters because external deals reduce dependence on a single discovery path and help fill future revenue gaps when older products lose exclusivity.

• $14.0B shows willingness to buy neuroscience assets.
• $4.1B shows willingness to buy radiopharmaceutical assets.
• $4.8B shows willingness to buy targeted oncology assets.

Global commercialization of medicines. This is the part of the model that converts approvals into cash flow. The latest full-year public revenue figure available in Company Name's reporting is $45.0B for 2023. That number matters because commercialization funds the next round of research, trials, and acquisitions. Global commercialization includes pricing, market access, medical affairs, sales execution, supply chain management, and lifecycle management across the United States and international markets.

• U.S. launch execution
• International launch execution
• Payer access and reimbursement
• Supply and distribution
• Lifecycle management

AI tool deployment. Company Name does not disclose a separate AI revenue line, AI segment, or standalone AI budget in public financial reporting, so the publicly disclosed amount is $0 for those items. AI therefore sits inside internal discovery, trial operations, and commercial workflows rather than as a reported business line.

Bristol-Myers Squibb Company - Canvas Business Model: Key Resources

7 products above $1B, $10B+ annual R&D spend, and $48.3B in 2024 revenue define Bristol-Myers Squibb Company's key resources.

Growth portfolio: Breyanzi, Reblozyl, Camzyos, Cobenfy, Opdualag, Sotyktu.

• 7 products above $1B
• Eliquis
• Opdivo
• Revlimid
• Orencia
• Pomalyst/Imnovid
• Reblozyl
• Breyanzi

Late-stage pipeline: Phase 3.

Annual R&D spend: $10B+.

Global commercial and manufacturing base: $48.3B.

Bristol-Myers Squibb Company - Canvas Business Model: Value Propositions

Bristol-Myers Squibb Company's value proposition is built on specialty medicines with large, durable revenue streams. In 2023, Bristol-Myers Squibb Company reported $45.0 billion in revenue, and Eliquis generated $12.2 billion in net product sales, equal to 27.1% of that total.

Innovative specialty medicines

Bristol-Myers Squibb Company sells prescription drugs for complex diseases that need specialist diagnosis, long treatment cycles, and strong reimbursement support. That matters because specialty medicines are not bought like low-cost primary care drugs. They depend on clinical evidence, physician adoption, payer coverage, and specialty pharmacy distribution. The company's scale gives it room to fund trials, manufacturing, and market access work at a level smaller biotech firms usually cannot match. The commercial model is concentrated, but the revenue per product can be very large when the medicine becomes a standard treatment in its category.

Broad oncology portfolio

Oncology is the biggest part of the company's value proposition. The portfolio includes Opdivo, Yervoy, Revlimid, Pomalyst, Abecma, Breyanzi, and Reblozyl. These products cover checkpoint inhibition, immunomodulation, cell therapy, and hematology-oncology. The 2019 Celgene acquisition for $74.0 billion was central to building this base. That transaction expanded the company's cancer and blood disorder reach and made oncology more than a single-product story. In business model terms, that reduces dependence on any one drug, while keeping the company positioned in one of the highest-value parts of medicine.

Cardiovascular and immunology therapies

The cardiovascular and immunology franchises make the company less dependent on oncology. Eliquis is the clearest example, with $12.2 billion in 2023 sales. Other products in this part of the portfolio include Camzyos, Orencia, Sotyktu, and Zeposia. This matters because it broadens relationships across cardiology, rheumatology, dermatology, neurology, and gastroenterology. It also spreads risk across different disease areas and prescriber groups. When one area slows, another can still support revenue and keep the company's specialty sales base stable.

New indications and pipeline expansion

Bristol-Myers Squibb Company uses label expansion and pipeline deals to keep existing medicines relevant and add new platforms. New indications can extend the commercial life of a drug without building a brand from zero. The company's recent deal activity shows that strategy clearly. Karuna Therapeutics added neuroscience exposure for $14.0 billion. RayzeBio added radiopharmaceutical capability for $4.1 billion. These moves matter because they expand the company beyond mature franchises and into areas where new clinical data can create more revenue over time.

Access expansion via ASPIRE

Access is part of the value proposition because specialty medicines only matter if patients can start and stay on treatment. That makes reimbursement, prior authorization, specialty pharmacy routing, and patient support part of the commercial model. ASPIRE fits that role by focusing on access expansion around specialty care. This is especially important in oncology and chronic disease settings, where treatment delays can reduce both clinical impact and prescription conversion. With $45.0 billion in 2023 revenue, Bristol-Myers Squibb Company has the scale to support access programs that help prescriptions turn into actual treatment.

• Specialist diagnosis
• Biomarker testing
• Prior authorization
• Specialty pharmacy distribution
• Infusion or hospital administration
• Patient navigation and reimbursement support

Bristol-Myers Squibb Company - Canvas Business Model: Customer Relationships

Bristol-Myers Squibb Company's customer relationships are built around $48.3B in 2024 revenue and approximately 34,100 employees, because its medicines depend on repeat interaction with physicians, hospitals, payers, and patients.

Long-term provider relationships

The provider base is built around specialty prescribing, hospital use, and account-level access. That matters because treatment decisions for oncology, hematology, immunology, cardiovascular disease, and neuroscience are often made by specialists rather than retail channels. The company's relationship model has to stay active across diagnosis, prescribing, reimbursement, administration, and follow-up, which is why commercial teams, medical teams, and reimbursement staff all sit inside the same customer loop.

• $48.3B 2024 revenue supports broad field coverage.
• 34,100 employees support commercial, medical, and operational contact points.
• 2 cell therapies, Breyanzi and Abecma, require treatment-center coordination.

Medical and regulatory support

Medical and regulatory support is part of the relationship because specialty drugs need label-compliant education, safety monitoring, and post-approval communication. For drugs that need safety monitoring, label updates, and treatment-center coordination, the medical relationship is as important as the sales relationship. In 2024, Bristol-Myers Squibb Company added Cobenfy, which expanded prescriber education into psychiatry.

• 2024 FDA approval for Cobenfy.
• 2 cell therapies in the marketed portfolio.
• $48.3B in 2024 revenue provides the base for medical affairs and compliance systems.

Patient access programs

Patient access is central because specialty medicines often face reimbursement checks before a patient starts therapy. The relationship work sits around eligibility, coverage, and continuity, not just the prescription date. Prior authorization, specialty pharmacy routing, and financial support all affect whether a patient gets from prescription to first fill.

Global pharma collaboration

Collaboration extends the relationship model beyond direct customers. The clearest example is the Pfizer partnership on Eliquis, which shares development, market access, and support work across two large pharmaceutical companies. That kind of relationship matters because it spreads risk, extends reach, and keeps the product tied to both prescribers and payers in multiple markets.

• 1 major co-commercialization partnership with Pfizer on Eliquis.
• 2 cell therapies that depend on external treatment networks.
• 2024 remains the latest full-year revenue base at $48.3B.

Bristol-Myers Squibb Company - Canvas Business Model: Channels

Bristol-Myers Squibb Company's channel model has 4 access paths: hospitals and clinics, specialty pharmacies, a global sales force, and regulatory and reimbursement pathways. The mix matters because the company reported $45.0 billion in 2023 net sales, and those sales depend on whether a therapy is given in a treatment center, filled by a pharmacy, or covered by a payer.

Hospitals and clinics

Hospitals and clinics are the main channel for provider-administered therapies. This matters for products that need infusion, close monitoring, or specialized handling. Breyanzi and Abecma are given as 1-time cell therapy infusions, while Reblozyl follows a recurring schedule such as every 3 weeks. In this channel, the hospital or clinic often buys the drug first and then bills the payer after administration. That is the buy-and-bill model. For you, the key point is that channel control sits with the treatment site, not the patient, so access depends on hospital stocking, staff capacity, prior authorization, and payer rules tied to the medical benefit.

• 1-time infusion therapies push demand through tertiary centers and infusion units.
• Recurring infusions create repeated billing events and repeat site-of-care decisions.
• Hospital access is especially important for oncology and cell therapy products.

Specialty pharmacies

Specialty pharmacies are the main channel for many oral therapies and long-duration treatments. Eliquis is taken 2 times daily, while Sotyktu, Camzyos, and Zeposia are once-daily therapies. This channel matters because the pharmacy benefit is different from the medical benefit: the patient fills the medicine through a pharmacy instead of receiving it in a clinic. Specialty pharmacies also handle benefit verification, refill timing, and adherence support. For Bristol-Myers Squibb Company, this channel is important for products that depend on chronic use, repeated refills, and low abandonment rates.

• Eliquis: 2 times daily.
• Sotyktu: 1 time daily.
• Camzyos: 1 time daily.
• Zeposia: 1 time daily.

Global sales force

The global sales force is the human channel that connects Bristol-Myers Squibb Company with physicians, hospital systems, and payer decision makers. It matters because prescriptions are written by clinicians, not by end customers. The field model supports 4 main customer groups in practice: oncologists, hematologists, cardiologists, and rheumatology or dermatology prescribers. The sales force does not replace the pharmacy or the hospital; it helps drive diagnosis, prescribing, pathway inclusion, and formulary placement. In academic work, this channel is useful because it shows how a pharmaceutical company creates demand before a prescription is filled.

• Physician education supports brand adoption after approval.
• Hospital account teams help with pathway and formulary access.
• Payer-facing teams help align clinical data with coverage rules.
• Field coverage is most valuable for complex specialty drugs.

Regulatory and reimbursement pathways

Regulatory and reimbursement pathways are a channel gate, not just a legal step. Bristol-Myers Squibb Company needs 2 approvals in practice before a drug creates steady sales: regulatory approval and payer coverage. In the U.S., that usually means FDA approval first, then reimbursement through Medicare Part B, Medicare Part D, Medicaid, or commercial plans. Outside the U.S., the company must work through EMA review and country-by-country payment decisions. This channel matters because clinical demand does not turn into revenue unless the medicine is approved, covered, and paid for. A therapy can have strong physician interest and still have weak sales if coverage is delayed.

• FDA approval opens the U.S. market.
• Medicare Part B usually matters for provider-administered drugs.
• Medicare Part D usually matters for pharmacy-dispensed drugs.
• EMA review and national reimbursement decisions shape ex-U.S. access.

Bristol-Myers Squibb Company - Canvas Business Model: Customer Segments

$48.3B in 2024 revenue depends on five quantified customer groups: oncology patients, cardiovascular patients, immunology patients, hematology patients, and the healthcare provider and payer layer. The largest measurable disease pools tied to Company Name are 20.0 million new cancer cases in 2022, 17.9 million cardiovascular deaths each year, and 18 million people living with rheumatoid arthritis globally.

Oncology patients are the largest measurable demand pool, with 20.0 million new cases and 9.7 million deaths worldwide in 2022, plus 2,001,140 new U.S. cases and 611,720 U.S. deaths in 2024. This segment includes solid tumors and blood cancers, so treatment depth matters more than volume alone. The patient pool is large enough to support broad clinical trial activity, repeated treatment lines, and high access pressure from payers.

• 20.0 million worldwide new cancer cases in 2022
• 9.7 million worldwide cancer deaths in 2022
• 2,001,140 U.S. new cancer cases in 2024
• 611,720 U.S. cancer deaths in 2024

Cardiovascular patients are a chronic-use segment, with 17.9 million cardiovascular deaths globally each year and about 33.5 million people worldwide living with atrial fibrillation. That size matters because long-term use creates repeated pharmacy claims, refill management, and payer dependence. For Company Name, this segment is tied to chronic therapy rather than a one-time intervention, so access continuity is central to revenue durability.

• 17.9 million cardiovascular deaths annually
• 33.5 million people worldwide with atrial fibrillation

Immunology patients are smaller than oncology in mortality terms but important in recurring prescriptions. Rheumatoid arthritis affects about 18 million people worldwide and about 1.5 million adults in the United States. These patients often stay on therapy for long periods, so adherence, safety monitoring, and payer renewal decisions matter more than a single start date. This segment rewards therapies that can hold access across multiple refill cycles.

• 18 million people worldwide with rheumatoid arthritis
• 1.5 million U.S. adults with rheumatoid arthritis

Hematology patients are a high-value specialty segment. Multiple myeloma accounted for 35,780 new U.S. cases in 2024 and 12,540 U.S. deaths in 2024. The treatment path often runs through academic centers, transplant centers, and infusion sites, so access is shaped by physician choice and payer rules. Smaller patient counts can still produce meaningful commercial value because treatment intensity and specialty care use are high.

• 35,780 new U.S. multiple myeloma cases in 2024
• 12,540 U.S. multiple myeloma deaths in 2024

Healthcare providers and payers are the access layer for all of these patients. They decide formulary status, prior authorization, site of care, and step therapy, so they influence whether the same 2,001,140 U.S. cancer cases, 35,780 U.S. multiple myeloma cases, 1.5 million U.S. rheumatoid arthritis patients, and 33.5 million people with atrial fibrillation worldwide can reach treatment. That is why payer access and provider adoption matter across BMS's $48.3B 2024 revenue base.

• 2,001,140 U.S. cancer cases in 2024
• 35,780 U.S. multiple myeloma cases in 2024
• 1.5 million U.S. rheumatoid arthritis patients
• 33.5 million people worldwide with atrial fibrillation

Bristol-Myers Squibb Company - Canvas Business Model: Cost Structure

R&D spending

Manufacturing and supply chain

Business development deals

Restructuring and layoffs

• 2,200 positions
• $1.5B expected annual savings
• 2025 target for completion

Litigation and compliance

Bristol-Myers Squibb Company - Canvas Business Model: Revenue Streams

$45.0 billion total revenues in 2023, driven by prescription drug sales.

Prescription drug sales

Eliquis $11.5 billion; Opdivo $9.3 billion; Revlimid $5.4 billion; Pomalyst/Imnovid $3.2 billion; Orencia $3.1 billion; Yervoy $2.6 billion.

Growth portfolio revenue

• Eliquis: $11.5 billion
• Opdivo: $9.3 billion
• Orencia: $3.1 billion
• Yervoy: $2.6 billion
• Zeposia: $0.8 billion

Legacy portfolio revenue

• Revlimid: $5.4 billion
• Pomalyst/Imnovid: $3.2 billion
• Abraxane: $1.1 billion
• Sprycel: $0.5 billion

Newly approved product sales

• Reblozyl: $1.2 billion
• Breyanzi: $0.6 billion
• Camzyos: $0.4 billion
• Opdualag: $0.4 billion
• Sotyktu: $0.2 billion

International product sales

• Eliquis outside the U.S.: $4.4 billion
• Opdivo outside the U.S.: $2.9 billion
• Revlimid outside the U.S.: $2.4 billion
• Pomalyst/Imnovid outside the U.S.: $1.9 billion
• Orencia outside the U.S.: $0.9 billion